Axa S.A. Zentalis Pharmaceuticals, Inc. Transaction History

Axa S.A.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$18.07 - $25.6 $4.13 Million - $5.86 Million	-228,827 Closed	0 $0
Q3 2022 Feb 14, 2023	BUY	$20.23 - $31.73 $19,926 - $31,254	985 Added 0.43%	228,827 $4.96 Million
Q3 2022 Nov 14, 2022	BUY	$20.23 - $31.73 $19,926 - $31,254	985 Added 0.43%	228,827 $4.96 Million
Q2 2022 Feb 14, 2023	BUY	$17.91 - $52.25 $1.69 Million - $4.93 Million	94,449 Added 70.81%	227,842 $6.4 Million
Q2 2022 Aug 15, 2022	BUY	$17.91 - $52.25 $1.69 Million - $4.93 Million	94,449 Added 70.81%	227,842 $6.4 Million
Q1 2022 Feb 14, 2023	SELL	$41.58 - $80.89 $3.97 Million - $7.72 Million	-95,434 Reduced 41.71%	133,393 $6.15 Million
Q1 2022 May 13, 2022	BUY	$41.58 - $80.89 $41 - $80	1 Added 0.0%	133,393 $6.16 Million
Q4 2021 Feb 14, 2022	BUY	$66.92 - $84.79 $106,469 - $134,900	1,591 Added 1.21%	133,392 $11.2 Million
Q3 2021 Nov 15, 2021	BUY	$46.83 - $73.5 $227,406 - $356,916	4,856 Added 3.83%	131,801 $8.78 Million
Q2 2021 Aug 13, 2021	SELL	$37.41 - $62.25 $1.39 Million - $2.31 Million	-37,067 Reduced 22.6%	126,945 $6.75 Million
Q1 2021 May 14, 2021	BUY	$35.69 - $52.72 $108,568 - $160,374	3,042 Added 1.89%	164,012 $7.12 Million
Q4 2020 Feb 12, 2021	BUY	$31.71 - $57.97 $154,839 - $283,067	4,883 Added 3.13%	160,970 $8.36 Million
Q3 2020 Nov 13, 2020	BUY	$27.03 - $47.97 $1.34 Million - $2.37 Million	49,444 Added 46.36%	156,087 $5.1 Million
Q2 2020 Aug 14, 2020	BUY	$23.2 - $54.8 $2.47 Million - $5.84 Million	106,643 New	106,643 $5.12 Million

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.